Your browser doesn't support javascript.
loading
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Hyman, David M; Piha-Paul, Sarina A; Won, Helen; Rodon, Jordi; Saura, Cristina; Shapiro, Geoffrey I; Juric, Dejan; Quinn, David I; Moreno, Victor; Doger, Bernard; Mayer, Ingrid A; Boni, Valentina; Calvo, Emiliano; Loi, Sherene; Lockhart, Albert C; Erinjeri, Joseph P; Scaltriti, Maurizio; Ulaner, Gary A; Patel, Juber; Tang, Jiabin; Beer, Hannah; Selcuklu, S Duygu; Hanrahan, Aphrothiti J; Bouvier, Nancy; Melcer, Myra; Murali, Rajmohan; Schram, Alison M; Smyth, Lillian M; Jhaveri, Komal; Li, Bob T; Drilon, Alexander; Harding, James J; Iyer, Gopa; Taylor, Barry S; Berger, Michael F; Cutler, Richard E; Xu, Feng; Butturini, Anna; Eli, Lisa D; Mann, Grace; Farrell, Cynthia; Lalani, Alshad S; Bryce, Richard P; Arteaga, Carlos L; Meric-Bernstam, Funda; Baselga, José; Solit, David B.
Afiliação
  • Hyman DM; Memorial Sloan Kettering Cancer Center, New York, New York, USA. hymand@mskcc.org.
  • Piha-Paul SA; University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Won H; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Rodon J; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Saura C; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Shapiro GI; Dana-Faber Cancer Institute, Boston, Massachusetts, USA.
  • Juric D; Massachusetts Hospital Cancer Center, Boston, Massachusetts, USA.
  • Quinn DI; USC Norris Comprehensive Cancer Center, Los Angeles, California, USA.
  • Moreno V; START Madrid Fundación Jímenez Díaz, Madrid, Spain.
  • Doger B; START Madrid Fundación Jímenez Díaz, Madrid, Spain.
  • Mayer IA; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
  • Boni V; START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain.
  • Calvo E; START Madrid, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain.
  • Loi S; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Lockhart AC; Washington University in St. Louis School of Medicine, St Louis, Missouri, USA.
  • Erinjeri JP; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Scaltriti M; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Ulaner GA; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Patel J; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Tang J; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Beer H; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Selcuklu SD; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Hanrahan AJ; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Bouvier N; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Melcer M; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Murali R; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Schram AM; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Smyth LM; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Jhaveri K; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Li BT; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Drilon A; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Harding JJ; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Iyer G; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Taylor BS; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Berger MF; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Cutler RE; Puma Biotechnology Inc., Los Angeles, California, USA.
  • Xu F; Puma Biotechnology Inc., Los Angeles, California, USA.
  • Butturini A; Puma Biotechnology Inc., Los Angeles, California, USA.
  • Eli LD; Puma Biotechnology Inc., Los Angeles, California, USA.
  • Mann G; Puma Biotechnology Inc., Los Angeles, California, USA.
  • Farrell C; Puma Biotechnology Inc., Los Angeles, California, USA.
  • Lalani AS; Puma Biotechnology Inc., Los Angeles, California, USA.
  • Bryce RP; Puma Biotechnology Inc., Los Angeles, California, USA.
  • Arteaga CL; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
  • Meric-Bernstam F; University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Baselga J; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Solit DB; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Nature ; 566(7745): E11-E12, 2019 02.
Article em En | MEDLINE | ID: mdl-30755741
The 'Competing interests' statement of this Article has been updated; please see the accompanying Amendment. The original Article has not been corrected online.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Nature Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Nature Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos